Newfound Research LLC lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 30.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,007 shares of the company’s stock after selling 448 shares during the period. Newfound Research LLC’s holdings in Merck & Co., Inc. were worth $78,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of MRK. OLD Mission Capital LLC purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter worth approximately $247,000. Schonfeld Strategic Advisors LLC grew its holdings in shares of Merck & Co., Inc. by 90.2% during the third quarter. Schonfeld Strategic Advisors LLC now owns 102,974 shares of the company’s stock worth $8,542,000 after purchasing an additional 48,825 shares in the last quarter. Rockland Trust Co. grew its holdings in shares of Merck & Co., Inc. by 12.2% during the fourth quarter. Rockland Trust Co. now owns 118,630 shares of the company’s stock worth $9,704,000 after purchasing an additional 12,887 shares in the last quarter. Stillwater Investment Management LLC grew its holdings in shares of Merck & Co., Inc. by 7.3% during the fourth quarter. Stillwater Investment Management LLC now owns 5,758 shares of the company’s stock worth $471,000 after purchasing an additional 390 shares in the last quarter. Finally, Red Spruce Capital LLC grew its holdings in shares of Merck & Co., Inc. by 1.9% during the fourth quarter. Red Spruce Capital LLC now owns 39,311 shares of the company’s stock worth $3,216,000 after purchasing an additional 719 shares in the last quarter. Institutional investors own 72.86% of the company’s stock.

Several analysts have weighed in on the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a research report on Friday, February 5th. SVB Leerink cut their target price on Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating on the stock in a research note on Friday. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $97.22.

Shares of Merck & Co., Inc. stock remained flat at $$75.98 on Tuesday. The stock had a trading volume of 382,596 shares, compared to its average volume of 11,885,203. The firm has a market capitalization of $192.26 billion, a price-to-earnings ratio of 16.81, a price-to-earnings-growth ratio of 1.89 and a beta of 0.43. The company has a current ratio of 1.30, a quick ratio of 1.00 and a debt-to-equity ratio of 0.90. The firm’s 50-day simple moving average is $76.83 and its 200-day simple moving average is $78.38. Merck & Co., Inc. has a 12-month low of $71.71 and a 12-month high of $87.80.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 29th. The company reported $1.40 EPS for the quarter, missing the Zacks’ consensus estimate of $1.63 by ($0.23). The company had revenue of $12.08 billion during the quarter, compared to analysts’ expectations of $12.71 billion. Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. Merck & Co., Inc.’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the firm posted $1.50 EPS. Equities analysts expect that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

Featured Article: How accurate is the Rule of 72?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.